Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04840563
Other study ID # ROC2-21-007
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 7, 2021
Est. completion date April 15, 2021

Study information

Verified date July 2021
Source Bausch & Lomb Incorporated
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 10 habitual soft contact lens wearing participants will be enrolled in this bilateral, randomized, double-masked (participant and investigator masked) repeated measures insertion study. All participants will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If participants satisfy all eligibility criteria and none of the exclusion criteria, participants will insert study lenses in random, successive order according to unique randomization schedules that will be provided to each Investigator.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date April 15, 2021
Est. primary completion date April 15, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Be 18 years or older and have full legal capacity to volunteer. 2. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. 3. Have no active ocular disease or allergic conjunctivitis. 4. Not be using any topical ocular medications. 5. Be willing and able to follow instructions. 6. Have signed a statement of informed consent. Exclusion Criteria: 1. Participating in a conflicting study in the opinion of the Investigator. 2. Considered by the Investigator to not be a suitable candidate for participation.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Kalifon A
Commercially available kalifilcon A lenses
Dailies Total1
Dailies Total1
Precision1
Precision1

Locations

Country Name City State
United States Bausch Site 001 Rochester New York

Sponsors (1)

Lead Sponsor Collaborator
Bausch & Lomb Incorporated

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Surface refractive index shifts Immediately following lens removal, the right eye worn lenses for each subject will be measured for surface refractive index on the refractometer. 10 minutes
See also
  Status Clinical Trial Phase
Completed NCT04555031 - Evaluation of Surface Refractive Index Shift of Kalifilcon A Lenses Compared to Dailies Total 1, Precision 1 and Biotrue ONEday Lenses N/A